MGEN vs. XGN, MDXH, SERA, OPGN, BDSX, BNR, ENZ, BGLC, ACON, and NTRA
Should you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Exagen (XGN), MDxHealth (MDXH), Sera Prognostics (SERA), OpGen (OPGN), Biodesix (BDSX), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), BioNexus Gene Lab (BGLC), Aclarion (ACON), and Natera (NTRA).
Miragen Therapeutics vs.
Exagen (NASDAQ:XGN) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation, community ranking and earnings.
Exagen has a net margin of -30.36% compared to Miragen Therapeutics' net margin of -1,393.50%. Exagen's return on equity of -92.58% beat Miragen Therapeutics' return on equity.
Exagen currently has a consensus target price of $7.50, suggesting a potential upside of 14.16%. Given Exagen's stronger consensus rating and higher possible upside, analysts clearly believe Exagen is more favorable than Miragen Therapeutics.
Exagen has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the S&P 500.
In the previous week, Exagen had 2 more articles in the media than Miragen Therapeutics. MarketBeat recorded 2 mentions for Exagen and 0 mentions for Miragen Therapeutics. Exagen's average media sentiment score of 0.63 beat Miragen Therapeutics' score of 0.00 indicating that Exagen is being referred to more favorably in the media.
Miragen Therapeutics received 239 more outperform votes than Exagen when rated by MarketBeat users. Likewise, 70.45% of users gave Miragen Therapeutics an outperform vote while only 62.22% of users gave Exagen an outperform vote.
75.3% of Exagen shares are held by institutional investors. 12.6% of Exagen shares are held by company insiders. Comparatively, 1.1% of Miragen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Exagen has higher revenue and earnings than Miragen Therapeutics. Exagen is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Exagen beats Miragen Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Miragen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Miragen Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MGEN) was last updated on 5/28/2025 by MarketBeat.com Staff
Buy MGEN Stock Free MGEN Stock Alerts